JSPR News and Press, Jasper Therapeutics Inc.

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous ...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.9% to $2.595 on volume of 386,733,662 shares Jet.AI Inc. (JTAI) rose 45.5% to $0.8149 on volume of 311,095,236 shares Hyperscale Data Inc. (GPUS) fell 4.0% to $0.3461 on volume o...

2026-01-08 11:44:52 ET Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria January 8, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Jasper Therapeutics, Inc. (JSPR) Di...

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks ...

2026-01-07 16:35:02 ET More on Jasper Therapeutics Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data - Slideshow Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Pr...

Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper...

2025-12-02 17:53:25 ET Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data December 2, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Jasper Therapeutics, Inc. (JSPR) Di...

2025-12-02 07:16:45 ET DENVER, Colo., Dec 02, 2025 ( 247marketnews.com )- Markets open today with a mix of AI-driven exuberance, biotech anticipation, and selective small-cap momentum as investors digest a heavy slate of company-specific catalysts heading into the first full week of Dec...